Alhusban Ahmed, Kozak Anna, Pillai Bindu, Ahmed Heba, Sayed Mohammed A, Johnson Maribeth H, Ishrat Tauheed, Ergul Adviye, Fagan Susan C
Program in Clinical and Experimental Therapeutics- Charlie Norwood VA Medical Center and College of Pharmacy, University of Georgia, Augusta, Georgia, United States of America.
College of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
PLoS One. 2017 Jun 22;12(6):e0178867. doi: 10.1371/journal.pone.0178867. eCollection 2017.
Stroke is a leading cause of adult disability worldwide. Improving stroke outcome requires an orchestrated interplay that involves up regulation of pro-survival pathways and a concomitant suppression of pro-apoptotic mediators. In this investigation, we assessed the involvement of eNOS in the AT1 blocker-mediated protective and pro-recovery effects in animals with hypertension. We also evaluated the effect of acute eNOS inhibition in hypertensive animals. To achieve these goals, spontaneously hypertensive rats (SHR) were implanted with blood pressure transmitters, and randomized to receive either an eNOS inhibitor (L-NIO) or saline one hour before cerebral ischemia induction. After 3 hours of ischemia, animals were further randomized to receive either candesartan or saline at the time of reperfusion and sacrificed either 24 hours or 7 days later. Candesartan induced an early protective effect that was independent of eNOS inhibition (50% improvement in motor function). However, the protective effect of candesartan was associated with about five fold up regulation of BDNF expression and about three fold reduction in ER stress markers, in an eNOS dependent manner. The early benefit of a single dose of candesartan, present at 24 hours after stroke, was diminished at 7 days, perhaps due to a failure to induce an angiogenic response in these hypertensive animals. In conclusion, our findings demonstrate an early prorecovery effect of candesartan at both functional and molecular levels. Candesartan induced prorecovery signaling was mediated through eNOS. This effect was not maintained at 7 days after experimental ischemia.
中风是全球成年人残疾的主要原因。改善中风预后需要精心协调的相互作用,这涉及促生存途径的上调以及对促凋亡介质的同时抑制。在本研究中,我们评估了内皮型一氧化氮合酶(eNOS)在高血压动物中AT1受体阻滞剂介导的保护和促进恢复作用中的参与情况。我们还评估了急性抑制eNOS对高血压动物的影响。为实现这些目标,给自发性高血压大鼠(SHR)植入血压传感器,在诱导脑缺血前1小时将其随机分为两组,分别接受eNOS抑制剂(L-NIO)或生理盐水。缺血3小时后,在再灌注时将动物进一步随机分为接受坎地沙坦或生理盐水两组,并在24小时或7天后处死。坎地沙坦诱导了一种早期保护作用,该作用与eNOS抑制无关(运动功能改善50%)。然而,坎地沙坦的保护作用以eNOS依赖的方式与脑源性神经营养因子(BDNF)表达上调约5倍以及内质网应激标志物减少约3倍相关。中风后24小时出现的单剂量坎地沙坦的早期益处,在7天时减弱,这可能是由于这些高血压动物未能诱导血管生成反应。总之,我们的研究结果表明坎地沙坦在功能和分子水平上均具有早期促进恢复的作用。坎地沙坦诱导的促进恢复信号是通过eNOS介导的。实验性缺血7天后这种作用未持续存在。